Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myeloproliferative Neoplasms: early-phase trial registry
6 of 9 indexed Myeloproliferative Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 6 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Myeloproliferative Neoplasms: 9 US clinical trials tracked, 6 recruiting.
Myeloproliferative Neoplasms is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Incyte Corporation, running 4 of these trials.
Enrollment posture brief
Registry condition myeloproliferative-neoplasms
OPEN 6 | RECR 67% | LATE 0 | EARLY 9 | RANK #1916 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Myeloproliferative Neoplasms lists 6 open slots (67% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myeloproliferative Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myeloproliferative Neoplasms is recruiting above its size-band peers.
6 of 9 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Myeloproliferative Neoplasms research.
Incyte Corporation accounts for 4 of 9 trials (44.4%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Myeloproliferative Neoplasms enrolment sits around 120 participants.
Median target enrolment is 120 among the 9 trials that report a genuine target (sentinel values excluded). 4 of those (44.4%) plan for fewer than 100 participants.
-
Myeloproliferative Neoplasms research is mostly interventional.
9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
NCT03314974
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
NCT06034002
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
NCT07441694
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
NCT06313593
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
NCT07008118
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
University of Chicago
NCT06291987
Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders
Memorial Sloan Kettering Cancer Center
NCT04761770
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Dana-Farber Cancer Institute
NCT03912064
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Alliance for Clinical Trials in Oncology
NCT00053196
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Myeloproliferative Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myeloproliferative Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myeloproliferative Neoplasms page
9 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Myeloproliferative Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Incyte Corporation sponsors the most Myeloproliferative Neoplasms trials on record, review their full trial history before evaluating a specific study. See Incyte Corporation's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myeloproliferative Neoplasms condition card totals 9 registered trials; most-linked intervention Standard disease-directed therapy; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.